Translate AMICOR contents if you like

Monday, January 30, 2017

Older Women: Breast Cancer

Good News for Older Women With Early Form of Breast Cancer

A diagnosis of DCIS doesn't lower life expectancy in patients over 50, study finds
By Robert Preidt
Friday, January 27, 2017
HealthDay news image
FRIDAY, Jan. 27, 2017 (HealthDay News) -- Older women treated for a very early form of breast cancer, called ductal carcinoma in situ (DCIS), do not have an overall increased risk of early death compared to their peers, a new study finds.
"Being diagnosed with DCIS can be extremely distressing, and research indicates that many women overestimate the risks involved and are confused about treatment. This study should provide reassurance that a diagnosis of DCIS does not raise the risk of dying," said Dr. Lotte Elshof. She is an epidemiologist at the Netherlands Cancer Institute in Amsterdam.
Elshof was to present the findings Friday at the European Cancer Congress in Amsterdam.
According to the National Breast Cancer Foundation, DCIS "is a noninvasive cancer where abnormal cells have been found in the lining of the breast milk duct. The atypical cells have not spread outside of the ducts into the surrounding breast tissue. Ductal carcinoma in situ is very early cancer that is highly treatable. . . ."
Untreated, DCIS can progress into invasive life-threatening breast cancer. However, it is usually treated with either surgery alone, or a combination of surgery and radiation therapy.
To determine the prognosis of older women diagnosed with DCIS, Elshof's team tracked 10-year outcomes for 10,000 Dutch women who were diagnosed with the condition between 1989 and 2004.
Women older than 50 who had been treated for DCIS actually had a 10 percent lower risk of dying from all causes combined, compared with women in the general population, the researchers found.
Specifically, the DCIS patients were less likely to die from other types of cancer and from circulatory, respiratory and digestive diseases, the findings showed.
"It might seem surprising that this group of women actually has a lower mortality rate than the general population. However, the vast majority would have been diagnosed via breast screening, which suggests they may be health-conscious and well enough to participate in screening," Elshof explained in a news release from the European Cancer Congress.
The study also looked at the risk of death from breast cancer. The investigators found that women treated for DCIS had a 2.5 percent risk of breast cancer death after 10 years, and a 4 percent risk after 15 years.
Both of those rates are higher than in the general population, Elshof's team noted. However, rates were lower in women whose DCIS had been diagnosed more recently, the study authors added.
And Philip Poortmans, president-elect of the European Cancer Organization, pointed out in the news release that "the increased risk of dying from breast cancer is completely offset by a lower risk of dying from other causes compared to women in the general population."
Two U.S. oncologists who reviewed the new study said it should reassure patients.
"The important take-away message is that women diagnosed with DCIS can be expected to live to a normal age as a whole," said Dr. Stephanie Bernik. She is chief of surgical oncology at Lenox Hill Hospital in New York City.
However, she agreed with the authors that there's a good explanation as to why women with DCIS tended to have better life expectancy than other women.
"If a woman is diagnosed with breast cancer, she will find herself with doctors' visits at every turn," Bernik noted. "This group of women is often encouraged to go to their primary medical doctor for any issue that may arise and screening for other cancers is more likely to occur. This may explain why women diagnosed with DCIS have a better overall survival."
Dr. Eleonora Teplinsky is an oncologist at Northwell Health Cancer Institute in Lake Success, N.Y. She called the new study "excellent," and said the next steps should look at "factors that contribute to the progression of DCIS to invasive disease."
Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.
SOURCES: Eleonora Teplinsky, M.D., medical oncologist, Northwell Health Cancer Institute, Lake Success, N.Y.; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; European Cancer Congress, news release, Jan. 27, 2017
HealthDay
News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.

Sunday, January 29, 2017

US-Mexico Border

Enviado por nossa filha Lújcia Helena

Infection and AD

Referência da AMICOR Maria Inês Reinert Azambuja

Could pathogen infection really lead to Alzheimer’s?

Published on January 12, 2017 at 6:37 AM ·
An interview with Dr Brian J. Balin conducted by , MA (Cantab)

What is the thinking behind the pathogen hypothesis of Alzheimer’s disease?

New concepts of infectious disease are evolving with the realization that pathogens are key players in the development of progressive chronic diseases that originally were not thought to be infectious.
Alzheimer's brain tissue
A light microscopic picture of human Alzheimer's brain tissue showing brown labeling with an anti-chlamydial antibody in a nerve cell. Chlamydia is marked in red brown. Image credit: The Balin Laboratory.
Infection is well-known to be associated with numerous neurological diseases for which pathologic effects have been well documented (Johnson, 1996). What has remained unclear, however, has been the role of infection as a causative or risk factor in the development of chronic neurodegenerative diseases.
In this regard, numerous studies over the past ~25 years have investigated whether there is an association between various infectious agents and Alzheimer’s disease, the most prevalent neurodegenerative condition accounting for dementia in the elderly.
Of the pathogens being considered in sporadic late-onset Alzheimer’s disease, Herpes Simplex Virus 1 (HSV-1) (Itzhaki et al, 1997), Borrelia species (Miklossy, 1993), and Chlamydia pneumoniae (Balin et al, 1998; Gerard et al, 2006) have garnered significant attention.
Work from other laboratories on systemic infectious disease (Kamer et al 2008, Cunningham et al, 2005) has also led to further interest in the role that infection may play in contributing to the neurodegenerative process in older populations.
Data from these investigations are intriguing, and have led to a renewed interest in investigating the role(s) of pathogens in the etiology of sporadic late-onset Alzheimer’s disease.
Furthermore, there is renewed interest in challenging long-held hypotheses in the Alzheimer’s research arena as investigations are uncovering more novel features of the amyloid protein as well as the inflammatory response associated with this disease.
The possibility of an infectious etiology of several chronic diseases, including Alzheimer’s disease (AD), has long been debated. Alzheimer, himself, over 100 years ago studied Treponema pallidum, the causative agent of syphilis, a spirochete later associated with dementia (Noguchi and Moore, 1913).
Sporadic late-onset Alzheimer’s disease, accounting for ~95-98% of all cases of Alzheimer’s disease, is thought to arise due to a multi-factorial interplay between genetic and environmental factors.
Speculation as to which environmental factors may have a great impact on the pathogenesis of this disease has resulted in studies of infectious disease.
This is a rational approach as different types of infections have been associated with dementing illnesses, including infection with Treponema pallidum, mentioned previously, as well as Cryptococcus neoformans (Hoffman et al, 2009), measles virus (Frings et al, 2002), and HIV (Zhou et al, 2010).
Early studies of infection directly related to Alzheimer’s disease attempted to correlate viral infection with late-onset disease (Pogo et al, 1987). Of the viruses considered were: Herpes Simplex 1 and 2, cytomegalo virus, measles virus, poliovirus, adenoviruses, hepatitis B virus, and the influenza A and B viruses. There was no association with disease determined for these viruses.
Later and more recent studies have found evidence for direct brain infection in AD with HSV1 (Itzhaki et al, 1997), Borrelia burgdorferi (Miklossy, 1993), and Chlamydia pneumoniae (Balin et al, 1998, Gerard et al, 2006).
There are some reports that even systemic infections may correlate to increased incidence of AD and infection with Helicobacter pylori, the agent of gastric ulcers and Porphyromonas gingivalis, an agent of periodontitis, have been studied in late-onset disease (see Honjo et al, 2009, Kim et al, 2007 for review).
Given these reports and the need to identify and understand causative factors for sporadic late-onset AD, much inquiry is needed to determine the mechanisms by which these different infections can initiate and participate in the pathogenesis of AD.
Interestingly, when one considers factors that may drive the accumulation of amyloid and tau in AD, infectious triggers are some of the most significant and logical choices; in particular, the organisms likely to be involved in AD are those that can evade host defenses, gain entry to specific selectively vulnerable regions of the brain, and establish chronic/persistent and/or latent infection. Upon considering the other risk factors found in AD, infection may be the central hub connecting these factors.
Currently, evidence from research on Chlamydia pneumoniae, Herpes Simplex Virus 1, and Borrelia burgdorferi in the AD brain, links numerous risk factors with infection to the pathogenesis of AD.
Linkage has been identified to risk factors including ApoEe4 expression, chronic neuroinflammation, autoimmune mechanisms, oxidative and mitochondrial damage, cardiovascular factors, diabetes with insulin resistance, trauma to the blood brain barrier and selectively vulnerable brain insult (for reviews see Journal of Alzheimer’s Disease, Vol. 13, #4, May 2008, pgs 357-463).
Thus, infection actually may be the overarching “unifying hypothesis” for sporadic late-onset AD, rather than other more mainstream hypotheses.

How much evidence is there to date that pathogens could be involved in the pathogenesis of Alzheimer’s?

If you search through pubmed or medline you will see that hundreds of peer-reviewed original research articles are indexed on infection in Alzheimer’s disease as you can see in this table.
SearchQuery Pubmed search performed as of 12/2/2016Items found
#9Search (pathogen and Alzheimer's disease)181
#8Search ((((infection and Alzheimer's disease)) NOT Reviews)) AND parasite10
#7Search ((((infection and Alzheimer's disease)) NOT Reviews)) AND fungus6
#6Search ((((infection and Alzheimer's disease)) NOT Reviews)) AND Fungal104
#5Search ((((infection and Alzheimer's disease)) NOT Reviews)) AND Bacteria188
#3Search ((((infection and Alzheimer's disease)) NOT Reviews)) AND viruses143
#2Search ((infection and Alzheimer's disease)) NOT Reviews702
#1Search infection and Alzheimer's disease1095

Which pathogens have you focused on in your research and why?

We have been studying infection within the AD central nervous system by Chlamydophila (Chlamydia) pneumoniae since the late 1990s. We believe that this unique intracellular bacterial organism plays a role in causing or contributing to late-onset sporadic Alzheimer’s disease (see Balin et al., 2008 – Journal of Alzheimer Disease for review).
In our first report of an association of C. pneumoniae with AD, we demonstrated by polymerase chain reaction (PCR) that the DNA of the organism was present in 90% of postmortem brain samples examined from sporadic AD (Balin et al., 1998).
A subsequent report from 2006 by us (Gerard et al) confirmed this finding in a different set of AD brains. As compared to the results in AD tissues, only 5% of postmortem brain samples from age-matched, non-AD, control individuals contained DNA from C. pneumoniae.
In the original and subsequent study, PCR was conducted using highly specific and sensitive probes for sequences of C. pneumoniae chromosomal DNA (Schumacher et al., 1999). Areas of the brain demonstrating significant neuropathology (eg, temporal cortices, hippocampus, parietal cortex, pre-frontal cortex) as well as areas less often demonstrating AD pathology (eg, cerebellum) were sampled by PCR.
Positive samples were obtained from at least one area demonstrating neuropathology, and in four cases, from the cerebellum. Interestingly, in the latter four cases, severe neuropathology was observed throughout, while in the two AD brains that were PCR-negative, very mild pathology was observed (Balin et al., 1998).
We have examined the role that C. pneumoniae plays in “triggering” events resulting in AD pathology following in vitro and in vivo (Little et al., 2004) infection with this organism. In vitro infections of the human cell lines, THP-1 monocytes and human brain microvascular endothelial cells (HBMECs), were designed to determine whether infection with C. pneumoniae influences the production and/or processing of cellular proteins found to be important in AD pathology.
Data from these studies suggested that C. pneumoniae infection of both cell types resulted in an increase in Ab 1-40 and Ab 1-42 immunoreactive peptides over the course of a 72hr infection.
The increase in immunoreactive fragments was determined following analysis of whole cell lysates. The processing of amyloid by these cell types, in addition to their activation to promote transmigration of peripheral monocytes through an in vitro blood brain barrier which we also demonstrated (MacIntyre et al., 2003), suggests that angiopathy and neuroinflammation could arise following local amyloid production and processing in the brain.
The influx of infected monocytes into the brain with ultimate production and processing of b-amyloid may provide a nidus of amyloid deposition that could promote further damage and/or “seeding” of further plaque development.
Entry of infected monocytes into the brain also may result in infection of resident microglia, astroglia, and neurons. Alternatively, a second pathway of infection through the olfactory neuroepithelia may lead to more direct infection of neurons in the specific limbic system regions of the brain such as the entorhinal cortex and hippocampal formation.
We believe that this olfactory route of infection actually may be the most important for the initiation of damage to the areas of the brain (ie, lateral entorhinal cortex and hippocampus) that are first involved with pathology in Alzheimer’s disease.
Alzheimer's brain tissue
Electron micrograph of a section of brain tissue from an Alzheimer's brain showing the chlamydial bodies inside a glial cell in the brain. The arrowheads point to what are termed reticulate bodies and the arrows point to elementary bodies - both types of bodies are different life forms of Chlamydia pneumoniae. . Image credit: The Balin Laboratory.

Why is this a controversial area?

This avenue of research remains controversial for a number of reasons.
  1. The “amyloid cascade hypothesis” has remained in favor for ~the past 30 years and the field is still fixated on this area even after ~430+ clinical trial failures with most of these trials based on this hypothesis.
  2. Different organisms have been identified to be associated with AD – many having been found in brain tissues, and others found systemically that could lead to neurological change – as there could quite well be a polymicrobial influence on this neurodegenerative condition, there may be multiple mechanisms behind manifestation of disease, Of the naysayers, they believe that not enough evidence has been found to change the existing paradigm for causation of AD.
  3. The fact that many of the infections that have been found in the disease are of a persistent, chronic and/or latent nature makes it difficult to assign starting points for when a person becomes infected and how this could result years later in Alzheimer’s disease.
  4. The lack of acceptance or understanding that a number of organisms, including Chlamydia pneumoniae and HSV1 can enter the brain by bypassing the blood brain barrier (ie, using our sense of smell) has resulted in a lack of appreciation for this process to initiate late-onset AD. Not enough neuropathologists understand how these types of organisms can promote inflammation and the generation of amyloid and/or tau pathology even though we and many others have demonstrated this experimentally after finding these organisms in human AD brains.
So, in general the vast majority of the AD research field has focused and continues to focus on the pathology that occurs in the disease and not on the initiating triggers for this pathology.

What further research is needed at this stage?

The further work needed at this stage is better understanding of mechanisms or pathways that are influenced by infection that lead to neuroinflammation and nerve cell damage that correlates to that observed in AD brains.
This would hold for both infections that actually enter and are found in the brain, as well as those that occur outside the brain but could influence neurological functioning.
Also, clinical trials to obtain biomarkers based on infections as well as those for treatment using antivirals, antibacterials, and anti-inflammatory drugs are required to establish how treating for infection can potentially influence onset and/or progression of disease following early diagnosis.
In addition, much more research is needed that involves the microbiome of the gut and pulmonary systems with regards to how these microbiomes can influence neurological health either directly or indirectly.
Furthermore, research on the anti-infective properties of amyloid must continue as this provides a rationale for why infection would be involved with late-onset Alzheimer’s disease and how amyloid generation and accumulation would be triggered to combat infection in the AD brain (Kumar et al, 2016; Spitzer et al, 2016).

In the future do you think it will be possible to develop diagnostic tools to determine who may be at risk for Alzheimer’s?

Yes, the current diagnostic tools of looking for biomarkers in blood and CSF have focused on differences in pathological markers such as those for beta amyloid and tau proteins, but also for lipids, inflammatory proteins, and antibodies to ingredients from cellular components from the nervous system.
Differences between those with AD and normals are trying to be correlated. We believe that eventually other biomarkers, especially those for infection such as antibodies to infecting agents and affiliated immune responses would be more realistic and specific for AD.
Also, using smell testing along with analysis of infection could be helpful for determining how the changes in sense of smell (which do occur early in AD) would indicate that infection is onboard in this region of the brain. This could result in very specific therapeutic regimens (even those delivered intranasally) that could eradicate or limit the effects of infection in this population.

Is it likely that Alzheimer’s could be a treatable condition one day?

Yes, but we must identify the triggers of the disease first and focus on eradicating the triggering mechanisms, in this case infections, by using antibiotics, antivirals or other anti-infectives.
In addition, we may be able to use anti-inflammatory therapies or immune modulating therapies that may minimize neuroinflammation.
Possibly, anti-amyloid therapies could then be used in conjunction to minimize the accumulation of amyloid plaques. However, current use of anti-amyloid therapies without eliminating the triggering insults have not been successful.

Do you think it will ever be possible to prevent the condition entirely? Could vaccines be a possibility?

Yes, with acceptance that infections along with other risk factors are involved with this disease, we could actually prevent the late-onset form of Alzheimer’s disease entirely.
Other risk factors that need to be better controlled for would include: atherosclerosis, diabetes, head trauma, systemic infection and respiratory problems including air pollution.
Vaccines could be a possibility, but those against certain infections, like Chlamydia pneumoniae and Herpes Simplex Virus 1 and may be even Lyme disease (Borrelia burgdorferi) would be required.
Vaccines against amyloid and other naturally occurring entities in the body are probably not going to be useful in this disease and, to date, have failed in clinical trials.

What are the main hurdles that need to be overcome in this field of research?

The main hurdles to be overcome at this point in time is the myopia of the Alzheimer’s research arena which has focused on an enormous amount research with regards to amyloid and tau proteins which comprise the main pathologies in this disease.
With over 430 clinical trial failures based principally on pathological entities, researchers, clinicians and the pharmaceutical companies must seriously start considering other research such as that on infection that correlates not only to the pathology observed, but also to the pathways damaged early in the disease process and the resultant consequences such as neuroinflammation that lead to accumulating and progressive damage that is observed in late-onset disease.

Where can readers find more information?

Readers can find more information on the web in a number of ways.
1. Googling my name and/or the role of infection in Alzheimer’s disease.
2. Going to our website which is www.pcom.edu and searching under research for Dr. Brian Balin.
3. Emailing me directly at: Brianba@pcom.edu.
4. Searching through the National Library of Medicine at www.ncbi.nlm.nih.gov/pubmed on infection in Alzheimer’s disease.

About Dr Brian J. Balin

BRIAN BALINDr. Brian J. Balin is the Chairman of the Department of Bio-Medical Sciences as well as a tenured full Professor of Experimental Neuropathology at Philadelphia College of Osteopathic Medicine.
In addition, Dr. Balin is the Director of the Center for Chronic Disorders of Aging, an Osteopathic Heritage Foundation endowed center, as well as the co-director of the Adolph and Rose Levis Foundation Laboratory for Alzheimer’s Disease Research at PCOM.
Dr. Balin is an internationally recognized expert in the field of Alzheimer's Disease research.
His research interests include: Infection with Chlamydia pneumoniae as a trigger in the neuroinflammation and neurodegeneration in Alzheimer's Disease, effects of infection and inflammation on the blood brain barrier in cerebrovascular disease, modification of neuronal cytoskeletal proteins through phosphorylation and the action of transglutaminase, and pathogenesis of chronic disease associated with the aging process.
Dr. Balin has received numerous National Institutes of Health and private foundation grant awards for his research. He is highly published in peer-reviewed journals, and has written a number of chapters and reviews on the pathology of Alzheimer's disease, including reviews on the "Pathogen Hypothesis" of this disease (see live discussion section, www.alzforum.org).
In addition, he has presented and continues to present his work at major national and international scientific meetings including a number of international and world congresses on Alzheimer's disease and related dementias.

References:

  1. Balin B. J., Gerard H. C., Arking E. J., Appelt D. M., Branigan P. J., Abrams J. T., Whittum-Hudson J. A. and Hudson A. P. (1998). Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain, Med Microbiol Immunol (Berl) 187, 23-42.
  2. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., and Perry V.H. (2005). Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neruodegeneration. J Neurosci 25, 9275-9284.
  3. Frings M., Blaeser I., Kastrup O. (2002). Adult-onset subacute sclerosing panencephalitis presenting as a degenerative dementia syndrome. J Neurol 249, 942-943.
  4. Gérard H. C., Dreses-Werringloer U., Wildt K.S. et al (2006). Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's Brain. FEMS Immunol Med Microbiol 48, 355-66.
  5. Hoffmann M., Muniz J., Carroll E., and De Villasante J. (2009). Cryptococcal meningitis misdiagnosed as Alzheimer's disease: complete neurological and cognitive recovery with treatment. J Alzheimer’s Dis. 16, 517-520.
  6. Honjo K., van Reekum R., Verhoeff N.P. (2009). Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?Alzheimers Dement 5, 348-60.
  7. Itzhaki R. F., Lin W. R., Shang D., Wilcock G. K., Faragher B., and Jamieson G. A. (1997). Herpes simplex virus type 1 in brain and risk of Alzheimer's disease [see comments], Lancet 349, 241-4.
  8. Johnson R.T. (1996). Emerging viral infections. Arch Neurol 53, 18022.
  9. Journal of Alzheimer’s Disease, Vol. 13, #4, May 2008, pgs 357-463
  10. Kamer A.R., Dasanayake A.P., Craig R.G., Glodzik-sobanska L., Bry M., and de Leon M.J. (2008). Alzheimer’s Disease and peripheral infections: The possible contribution from periodontal infections, model and hypothesis. J Alzheimer’s Dis. 13, 437-449.
  11. Kim J.M., Stewart R., Prince M., Kim S.W., Yang S.J., Shin I., and Yoon J.S. (2007). Dental health, nutritional status and recent-onset dementia in a Korean community population. Int J Geriatr Psychiatry 22, 850-855.
  12. Miklossy J. (1993). Alzheimer's disease--a spirochetosis?, Neuroreport 4, 841-8.
  13. Noguchi H., and Moore J.W. (1913). A demonstration of Treponema pallidum in the brain of general paralysis cases. J Exp Med 17, 232-238.
  14. Pogo B.G., Casals J., Elizan T.S. (1987). A study of viral genomes and antigens in brains of patients with
  15. Alzheimer’s diseaseBrain 110, 907-15.
  16. Zhou L., Diefenbach E., Crossett B., Tran S.L., Ng t., Fizos H., Rau R., et al. (2010). First evidence of overlaps between HIV-associated dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia. Mol Neurodegener 5, 1-20.

2799 - AMICOR 19

FLP-7

Aloyzio AchuttiemAMICOR - Há 17 horas
[image: villi small intestine] FLP-7 Neuropeptide Hormone Triggers Serotonin To Drive Fat Loss Florian Rosado January 28, 2017 A brain hormone that appears to trigger fat burning in the gut has been identified by biologists at The Scripps Research Institute (TSRI). The finding in animal models could have implications for future pharmaceutical development. TSRI Assistant Professor Supriya Srinivasan, senior author of the new study, said: “This was basic science that unlocked an interesting mystery.” Previous studies had shown that the neurotransmitter serotonin can drive fat loss. Y... mais »

The World Post Weekend Roundup

Aloyzio AchuttiemAMICOR - Há 21 horas
*THE WEEKEND ROUNDUP * No sooner did “the party of Davos” ― as top White House aide Stephen Bannon calls the global elite ― end its annual conclave in the Swiss Alps late last week than the “Nationalist International” was born down in the Rhine Valley city of Koblenz, Germany. All the main populist movements from across Europe gathered together there to celebrate the Brexit and Trump victories as a premonition of their own expected success in elections over the coming year. They called on their fellow Europeans to “wake up” like the Americans and British and take back control of the... mais »

Luiz Cechella. Nosso avô materno.

Aloyzio AchuttiemAMICOR - Há 22 horas
*Por Luiz Binato em A Razão de hoje - Santa Maria, RS* *Eu (neto do Luiz) e nossos netos Pedro, Antônio e Eduardo, aos 15 também...*

Prenatal AD origins

Aloyzio AchuttiemAMICOR - Há um dia
Alzheimer’s Roots May Extend Back As Far As the Womb *Summary: A lack of vitamin A during pregnancy or shortly after birth may facilitate Alzheimer’s disease later in life, a new study reports.* *Source: University of British Columbia.* *Vitamin A deficiency could ‘program’ brain tissue.* Biochemical reactions that cause Alzheimer’s disease could begin in the womb or just after birth if the fetus or newborn does not get enough vitamin A, according to new research from the University of British Columbia. These new findings, based on studies of genetically-engineered mice, also demons... mais »

Laniakea

Aloyzio AchuttiemAMICOR - Há 2 dias
https://youtu.be/rENyyRwxpHo - Space.com - Science & Astronomy New Galactic Supercluster Map Shows Milky Way's 'Heavenly' Home By Charles Q. Choi, Space.com Contributor Esta simulação de computador retrata o superaglomerado gigante, com a localização da Via Láctea mostrada como um ponto vermelho A nossa galáxia, Via Láctea, fica dentro de um superaglomerado gigante. Agora, um novo mapa cósmico criado por pesquisadores da Universidade do Havaí em Honolulu nos oferece um olhar sem precedentes sobre os limites dessa nossa casa celestial./.../

Brain Pollution

Aloyzio AchuttiemAMICOR - Há 2 dias
The polluted brain 1. Emily Underwood* Science 27 Jan 2017: Vol. 355, Issue 6323, pp. 342-345 DOI: 10.1126/science.355.6323.342 Summary Some of the health risks of inhaling fine and ultrafine pollutant particles are well-established, such as asthma, lung cancer, and, most recently, heart disease. But a growing body of evidence suggests that such exposure can also harm the brain, accelerating cognitive aging, and may even increase risk of Alzheimer's disease and other forms of dementia. The link between air pollution and dementia remains controversial—even its proponents warn tha... mais »

DIABETES outcomes?

Aloyzio AchuttiemAMICOR - Há 2 dias
January 26, 2017 From |The JAMA Netoworks Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? Kasia J. Lipska, MD, MHS1; Harlan M. Krumholz, MD, SM2,3 Author Affiliations Article Information JAMA. Published online January 26, 2017. doi:10.1001/jama.2017.0029 The goals of treatment of type 2 diabetes are to reduce the risk of diabetic complications and, as a result, improve the quality and, possibly, duration of life. For several decades, authoritative guidelines instructed clinicians to strictly control glucose levels of patients with diabetes to accomplish these goals. In add... mais »

ZH - Flávio Kanter: Incerteza em Medicina

Aloyzio AchuttiemAMICOR - Há 2 dias
Artigo na ZH de hoje de meu amigo AMICOR Flávio Kanter. Entre tantos artigos que ele tem escrito, este eu não poderia deixar de reproduzir. Até deu ânimo para terminar um inacabado sobre Realidade e Imaginação. Obrigado e Parabéns!...

WHO

Aloyzio AchuttiemAMICOR - Há 2 dias
Trois candidats pour diriger une OMS en quête de confiance Le Comité exécutif de l’Organisation mondiale de la santé a désigné mercredi à Genève les trois candidats finalistes qui souhaitent succéder à la Chinoise Margaret Chan. Le moment est crucial. La crise Ebola a mis en évidence les faiblesses de l’organisation

Microbioma

Aloyzio AchuttiemAMICOR - Há 3 dias
NSF awards $3 million for plant and animal microbiome and phenomics research 01/24/2017 06:00 AM EST [image: New research on plant and animal microbiomes will lead to advances in human health, agriculture.] Millions of microbes living on and in the human body collectively make up our microbiomes. These microbial ecosystems help keep us healthy. The same processes are at work in other animals, as well as in plants. To better understand the role microbiomes play in human health and in ecosystems around the world, the National Science Foundation's (NSF) Directorate for Biological Science... mais »

Supercluster Vela

Aloyzio AchuttiemAMICOR - Há 3 dias
O vizinho colossal da Via Láctea ED. 251 | JANEIRO 2017 © THOMAS JARRETT (UCT)/INSTITUTO MAX PLANCK [image: A Via Láctea(em azul e branco, no eixo horizontal) e a localização do novo supercluster Vela (VCS) e do supercluster Shapley (SC)] A Via Láctea (*em azul e branco, no eixo horizontal*) e a localização do novo supercluster Vela (VCS) e do supercluster Shapley (SC) Um dos maiores superclusters de galáxias foi descoberto perto da Via Láctea por astrofísicos da Europa, Austrália e África do Sul (*Monthly Notices of the Royal Astronomical Society*, 8 de novembro). Denominado superclus... mais »

Shameless Lying?

Aloyzio AchuttiemAMICOR - Há 3 dias
UNDAY, JANUARY 22, 2017 Why Do Political Figures Lie So Blatantly? *Are They Pathological Liars? Narcissists? Psychopaths? “Masterful Manipulators”? * Trump Spokesman’s Lecture on Media Accuracy Is Peppered With Lies Nearly all American politicians lie, but few as blatantly as those affiliated with the present administration. How do they do it? Are they lacking a conscience? Do they believe their own lies? Do they start with small falsehoods, stretch the truth, reinterpret events, and finally graduate to verifiably false statements? “This was the largest audience to ever witness an... mais »

How to fix it

Aloyzio AchuttiemAMICOR - Há 3 dias
Something Broken? Learn To Fix Anything With These 4 Websites Dann Albright May 8, 2014 5 minutes No one likes it when their things break. It might be something big, like your TV or your car, or something smaller, like a leaky faucet or a cracked floor tile. You can spend hundreds of dollars to have a professional help you out, or you can learn how to fix it yourself for the cost of some tools and a couple hours of work. Which would you rather do? Be Safe! Before you go trying to fix all of your problems by yourself, make sure that you’re making safe decisions. If something really exp... mais »

Climate: 50 Years Ago

Aloyzio AchuttiemAMICOR - Há 4 dias
The Jan. 27, 1967, cover of TIME Cover Credit: LARRY LEE MEDIA 50 Years Ago This Week: Worry Over Climate Change Has Already Begun Lily Rothman Jan 23, 2017 [image: Jan. 27, 1967]*Milestone moments do not a year make. Often, it’s the smaller news stories that add up, gradually, to big history. With that in mind, in 2017 TIME History will revisit the entire year of 1967, week by week, as it was reported in the pages of TIME, to see how it all comes together. Catch up on last week’s installment here.* Week 4: Jan. 27, 1967 Illustrated with several pages of color photos, this cover story... mais »

Geriatrics 2016

Aloyzio AchuttiemAMICOR - Há 4 dias
From: Wiley Geriatrics *JAGS’ Top 15 Most Talked About Articles in 2016* Here are the top 15 articles published in the *Journal of the American Geriatrics Society (JAGS)* in 2016 as measured by Altmetric, which provides a measure of the quality and quantity of online attention each article receives in traditional news outlets and on social media. Click the @AGSJournal twitter summaries to learn more. Can a Healthy Lifestyle Compress the Disabled Period in Older Adults? ● *@AGSJournal: Walking greater distances and having a better diet is associated with a compression of the period sp... mais »

Meditation, Music and Memory

Aloyzio AchuttiemAMICOR - Há 5 dias
Meditation and Music May Help Reverse Early Memory Loss in Adults NEUROSCIENCE NEWSJANUARY 23, 2017 *Summary: Researchers report practicing simple meditation and listening to music can have benefits for those with preclinical memory loss.* *Source: IOS PRESS.* *Meditation and music improve memory and cognitive function in adults with subjective cognitive decline: A pilot randomized controlled trial.* In a recent study of adults with early memory loss, a West Virginia University research team lead by Dr. Kim Innes found that practice of a simple meditation or music listening program may ... mais »

UHC - Frustrações x Realidade...

Aloyzio AchuttiemAMICOR - Há 5 dias
*Recebi de um amigo - Vitor Gomes Pinto - a propósito da "Universal Health Coverage" ou "Right Care for Health", ou "Health for All".* *Vale sonhar enquanto subsistem o genocídio, o extermínio de inocentes, a morte por fome e desnutrição, a disputa de gangues pelo poder e pelo mercado, a corrupção desenfreada, etc...?* O texto abaixo, publicado na Lancet acessível hoje, parece um esforço dos "pensadores" da burocracia internacional para se livrarem "suavemente" de um negócio que não funcionou - a UHC - Universal Health Coverage. No texto que há poucos meses publiquei no site a respei... mais »

NEJM Year in Review 2016

Aloyzio AchuttiemAMICOR - Há 5 dias
NEJM Journal Watch General Medicine Year in Review 2016 - FREE! Download Now View in browser [image: NEJM Journal Watch] NEW FREE COLLECTION NEJM Journal Watch General Medicine NEJM Journal Watch General Medicine Year in Review 2016 - FREE! Download Now View in browser [image: NEJM Journal Watch] NEW FREE COLLECTION NEJM Journal Watch General Medicine Year in Review 2016 Get this exclusive collection – FREE for a limited time *Download Now* To thank you for being a valued reader of NEJM Journal Watch, we’re excited to offer you exclusive access to the *NEJM Journal Watch General Medicine ... mais »

The Harvard Classics

Aloyzio AchuttiemAMICOR - Há 6 dias
*E dizer que há mais de 30 anos fui comprando mensalmente esta coleção (custava cerca de US$50 cada volume)... Agora estão ao alcance do computador, e de graça...* The Harvard Classics: Download All 51 Volumes as Free eBooks in *Books, Education, Literature*| March 12th, 2014 45 Comments [image: harvardclassics-e1309476756550] Every revolutionary age produces its own kind of nostalgia. Faced with the enormous social and economic upheavals at the nineteenth century’s end, learned Victorians like Walter Pater, John Ruskin, and Matthew Arnold looked to High Church models and played the bi... mais »

Anhedonia

Aloyzio AchuttiemAMICOR - Há 6 dias
*Sciencebeta* ‏@sciencebeta 6h6 hours ago More Lack of joy from music linked to brain disconnection http://bit.ly/2jc2SrD Denise Rosenfeld January 5, 2017 People who are just not into music at all may have a condition called specific musical anhedonia. It affects three-to-five per cent of the population. Individuals with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward, researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of McGill Uni... mais »